On May 7, 2026, Lemaitre Vascular Inc. (NASDAQ: LMAT) director Lawrence J. Jasinski executed a notable series of transactions involving the company's common stock. According to recent filings, Mr. Jasinski sold 3,943 shares at a price of $110.00 per share, resulting in a total transaction value of $433,730.
This sale price of $110.00 per share reflects a premium over the current stock price of $101.64. For context, the stock is currently trading near its 52-week high of $118.01 and has seen a year-to-date return of 33%. Despite this upward momentum, valuation analysis suggests that the company appears overvalued at these levels, noting a price-to-earnings (P/E) ratio of 37.67.
Details of Option Exercises and Holdings
The sale was preceded by the acquisition of 2,858 shares through the exercise of stock options on the same day. These acquisitions totaled $188,411, with individual share prices ranging from a low of $47.19 to a high of $101.12. The breakdown of these exercises is as follows:
- 1,069 shares acquired at $47.19 per share (this block was fully vested and exercisable).
- 924 shares acquired at $54.65 per share.
- 865 shares acquired at $101.12 per share.
Regarding the vesting schedules, the options for 924 and 865 shares are subject to a three-year vesting period. Under these terms, 33.3% of the options vest on the first anniversary of their respective grant dates, with the remaining balance vesting in equal annual installments over the following two years. Following the completion of these transactions, Lawrence J. Jasinski maintains a direct holding of 4,714 shares of Lemaitre Vascular common stock.
Recent Financial Performance and Analyst Outlook
These insider movements occur against a backdrop of strong recent financial results for Lemaitre Vascular. The company reported its first-quarter 2026 earnings, which outperformed analyst projections. Specifically, the company posted earnings per share (EPS) of $0.68, surpassing the anticipated $0.66. Revenue also exceeded expectations, with the company reporting $66.6 million compared to a forecast of $66.57 million.
Following these results, Citizens updated its outlook for LMAT, raising the price target from $118 to $128 while maintaining a Market Outperform rating. This upward revision was driven by improved expectations for profit and margins, supported by the first-quarter performance and updated guidance for the full year of 2026. Analysts noted that total sales remained consistent with quarterly guidance, showing organic year-over-year growth of 10%.